Trial Type: Early Phase Trials for Multiple Cancer Types

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

Phase 1 Study of ACR-2316 in Subjects with Advanced Solid Tumors

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent and in Combination in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair

A Phase 1a/1b Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination with Other Anti-tumor Agents in Patients with Locally Advanced or Metastatic Tumors

A Phase I, first-in-human, open-label, dose escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of BNT317 in patients with advanced solid tumors

An Open-Label, Multicenter, Phase 1/1b Study Of Janx008 In Subjects With Advanced Or Metastatic Solid Tumor Malignancies

An Open-Label, Multicenter, Dose Escalation, Randomized, Phase I Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Anti-Tumor Activity Of Ro7567132 As Single Agent And In Combination With Atezolizumab In Participants With Advanced And/Or Metastatic Solid Tumor

A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors

A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient

A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors